Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) have been given an average broker rating score of 1.75 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company.

Analysts have set a twelve-month consensus price target of $31.25 for the company and are anticipating that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Rhythm Pharmaceuticals an industry rank of 161 out of 265 based on the ratings given to related companies.

A number of equities research analysts have recently issued reports on the company. BidaskClub cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Cowen reiterated a “buy” rating and set a $40.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. Morgan Stanley assumed coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “equal weight” rating and a $23.00 price objective on the stock. Finally, Bank of America assumed coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $30.00 price objective on the stock.

Shares of Rhythm Pharmaceuticals (RYTM) traded up $0.45 during trading on Tuesday, hitting $27.40. The stock had a trading volume of 31,892 shares, compared to its average volume of 161,465. Rhythm Pharmaceuticals has a one year low of $21.38 and a one year high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($1.38). research analysts forecast that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current year.

WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/14/1050728.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit